Endocrine Abstracts

Objectives: Metabolic dysfunction–associated fatty liver disease (MAFLD) is a new nomenclature for fatty liver disease (FLD). The clinical impact of the change in nomenclature on the ability to identify individuals at risk for cardiovascular disease (CVD) has not yet been elucidated. The aim of this study is to describe the cardiovascular risk and subclinical CVD of the different MAFLD subtypes.Methods: Retrospective analysis of patients who attende...

Patients with impaired glucose metabolism, either prediabetes (preD) or type 2 Diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD) have a higher prevalence of cardiovascular events. Recent studies have shown a relationship between epicardial fat and myocardial ischemia.Objective: To determine whether hepatic fibrosis assessed by liver elastography (LE) or Fibrosis-4 (FIB-4) score correlates with epicardial fat volume quantified by computed tomo...